Immune-based therapies for hepatocellular carcinoma

167Citations
Citations of this article
138Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.

Cite

CITATION STYLE

APA

Pinato, D. J., Guerra, N., Fessas, P., Murphy, R., Mineo, T., Mauri, F. A., … Rimassa, L. (2020, April 30). Immune-based therapies for hepatocellular carcinoma. Oncogene. Springer Nature. https://doi.org/10.1038/s41388-020-1249-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free